



MEDICAL TIPS

K-MET Tablets

Issue XI, No.42, 2023

Impact of metformin on statin-associated myopathy risks in dyslipidemia patients

Bak k et al. Pharmacology Research and Perspectives 2023; 11(4):e01114.

- A growing number of patients with metabolic disorders are receiving statin and antidiabetic therapies as comedications and a signal of increased risk of myotoxicity due to potential interactions between antidiabetics and statins has been detected earlier.
- The effects of metformin on myopathy risks when added to preexisting statin therapy in dyslipidemia patients was evaluated.
- A retrospective cohort study was conducted where the risk of myopathy was compared in stain + metformin (n=4092) users against statins-only users (n=8161).
- The risk of myopathy was decreased when metformin was used together with statins.

Metformin may provide protective effects on the potential muscle toxicities induced by statin therapy



